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Background
Postpartum haemorrhage (PPH) is a leading cause of maternal 
mortality world-wide and the incidence appears to be increasing1. 
Most deaths are in low-and-middle income countries. Immediate 
and appropriate management of PPH is essential to reduce 
mortality and morbidity. The antifibrinolytic tranexamic 
acid (TXA) reduces bleeding by inhibiting the enzymatic 
breakdown of fibrin blood clots. Plasminogen is converted into 
the fibrinolytic enzyme plasmin by tissue plasminogen activator. 
TXA is a synthetic lysine analogue which blocks the lysine 
binding sites on plasminogen, as a result inhibits binding of 
plasminogen or plasmin with fibrin and thereby inhibiting fibrin 
degradation. It has the half-life about two hours and is excreted 
mostly by the kidneys2. 
The CRASH 2 trial3 showed that TXA significantly reduces 
death due to bleeding in trauma patients without any increase in 
thromboembolic events when given within 3 hours of injury. 
More recently, the WOMAN trial4, showed that TXA significantly 
reduces death due to bleeding in women with PPH. Once again 
there was no evidence of any increase in thromboembolic 
events. On the basis of these results, TXA is recommended for 
the treatment of PPH and should be administered as soon as 
possible after onset of bleeding and within 3 hours of birth5.
Although plasmin increases fibrin clot breakdown, it may also 
have effects on coagulation and platelets. Plasmin activates 
coagulation factors V and VIII6,7 and increases thrombin 
generation8. Plasmin stimulates platelet aggregation, 
degranulation, complement activation and platelet activation6,9,10. 
If these effects are mediated via lysine binding sites then it is 
possible that they might be affected by TXA administration. We 
conducted a sub-study within the WOMAN trial to investigate 
the effects of TXA on coagulation and platelets.
Objective
To assess the effects of TXA treatment on endogenous thrombin 
potential (ETP) and platelet function. If plasmin activation increases 
ETP and stimulates platelet activation, we would expect TXA to 
reduce ETP and inhibit platelets.
Methods and study design
The full ETAPlaT protocol is available from 11.
Study design and participants
We conducted a sub-study within the WOMAN trial, an 
international randomized, parallel-group, double blinded, placebo- 
controlled trial. The study included adult women with primary PPH. 
The PPH diagnosis was based on the visual estimation of blood 
loss (>500 mL after vaginal birth or ≥1,000 mL after caesarean 
birth or blood loss sufficient to cause hemodynamic instability). In 
addition to the usual treatment for PPH, women were randomized 
in the study as soon as possible after informed consent had been 
obtained. The main criterion for eligibility was the uncertainty of 
clinician to use or not use TXA in a particular woman diagnosed 
with PPH. The study was carried out according to the guidelines of 
good clinical practice12 and adhered to the regulatory requirements 
for Albania.
Ethical approvals for the study were obtained from the London 
School of Hygiene and Tropical Medicine (LSHTM) and the 
National Ethics Committee in Tirana, Albania. Brief information 
about the study was given to pregnant women. All eligible 
women underwent the informed consent procedure for the 
WOMAN trial as well as for the ETAPlat sub-study before 
randomization. The detailed consent procedure is reported at the 
ETAPlaT protocol11. The ETAPlaT study was carried out at the 
Obstetric Gynaecology University Hospital “Koço Gliozheni” 
in Tirana, Albania. There are approximately 4500 deliveries per 
year in this hospital, which offers tertiary level health care and 
is a referral centre for other maternity hospitals at the country.
Randomization and blinding
Women with PPH, who fulfilled the eligibility criteria and 
completed the consent procedures, were randomized in the study 
and were allocated to receive either TXA or placebo. ETAPlaT 
as a sub-study of WOMAN trial utilised the same randomization 
and blinding procedures. In summary, the trial treatment packs 
were identical, so both patients and healthcare workers were 
blinded to treatment allocation. Each box contained eight 
individual treatment packs, each pack contained two doses of 
study drugs (one dose contained: 2 vials each TXA 500mg-5 mL, 
or 2 vials each 5mL sodium chloride 0.9%). The packs were 
used in sequential order by the caregiver starting from the lowest 
numbered pack.
Interventions and laboratory procedures
As soon as the patient was randomized in the study, alongside with 
the usual treatment for PPH, the trial treatment was administered 
by slow intravenous injection, 1mL/minute, of 1 gram TXA or 
placebo. A second dose of study drugs was administered if 
haemorrhage did not stop after 30 minutes or restart within 
24 hours of the first dose.
Baseline blood sample was collected immediately after 
randomization and before the first dose was administered. Three 
mL of venous blood was collected in hirudine (25μgr/mL) test 
tube - double wall (Dynabyte, Munich, Germany) for multiple 
electrode aggregometry (MEA) and 5 mL in tri-sodium citrate 
0.106 mol/lˉ¹ (S-Monovette, Sarstedt, Germany) for coagulation 
tests. The same procedure for blood collection was performed 
at 30±15 minutes after the first dose study drug administration. 
Follow-up blood collection procedure was performed always 
before administration of the second dose of study treatment, if 
it was needed.
Baseline and follow-up samples were analysed for platelet function 
(ADPtest and TRAPtest) performing MEA with Multiplate. Details 
of methods used for ADPtest have been previously reported13 
and for TRAPtest14. All material used forTRAPtest and ADPtest 
including Multiplate equipment, were obtained from the 
manufacturer (Dynabyte GmbH, Munich, Germany). The 
recorded platelet aggregation measured by MEA was expressed 
as area under curve (AUC) AU*min. The platelet function 
analysis using MEA was performed by the laboratory at 
Hospital “KoçoGliozheni” in Tirana, Albania.
The blood samples obtained in 5 mL in sodium citrate test 
tubes for coagulation analysis were immediately centrifuged 
at 3000xg for 20 min. The acquired platelet poor plasma was 
divided in two aliquots and preserved in deep freeze (-80°C) 
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until the laboratory analysis at the end of the study. The coagula-
tion tests were performed at the Institute of Laboratory Medicine, 
German Heart Centre in Munich, Germany. The thrombin 
generation assay (TGA) was performed with Calibrated 
Automated Thrombogram (Stago Deutschland GmbH). The 
coagulation factors V, VIII, von Willebrand, Fibrinogen (Claus 
method) and D-Dimer were analyzed with SIEMENS BCS XP 
Coagulation Analyzer, using reagents FV and FVIII deficient 
plasma, Multifibren*U fibrinogen reagent, BC von Willebrand 
reagent and INNOVANCE® D-Dimer reagent, all reagents were 
obtained from Siemens Healthcare Diagnostic Products GmbH, 
Marburg, Germany.
Outcomes
The primary outcome was the change (baseline versus follow-up) 
in ETP. Secondary outcomes included the change (baseline ver-
sus follow-up) in platelet function (ADPtest and TRAPtest) and 
coagulation factors V, VIII, von Willebrand, Fibrinogen, D-Dimer 
on baseline and follow-up blood samples. Thrombin generation 
was chosen as the primary outcome because it is a surrogate for 
coagulation activity15 and factors that increase thrombin formation 
can potentially increase thrombotic risk16.
Statistical analysis
The statistical analysis plan to the ETAPlat Study was published 
and reviewed before database lock17. The study evaluates the 
effect of TXA compared to placebo by quantifying the change over 
time (baseline minus follow-up) in the primary outcome ETP and 
a series of secondary outcomes. The study therefore compares the 
changes between baseline and follow up in the TXA and placebo 
groups (the difference in the differences).
The sample size calculation was based on the following assump-
tions: ETP is normally distributed with a mean of 2410 nM*min and 
standard deviation (SD) of 543 nM*min18. We assume a decrease 
in ETP of 10% (241 nM*min) in the TXA group and no change 
in the placebo group. The calculation of the difference’s standard 
error is based on a correlation of 0.6 between two time points 
and uses the standard deviation reported by McLean18. To detect 
an ETP difference in differences of 241 nM*min between groups 
at a 5% significance level with a power of 90%, two groups each 
with 88 patients are needed.
We compared before and after changes in coagulation parameters 
between treatment groups using repeated measurement ANOVA. 
An intention-to-treat analysis was performed by using analysis of 
covariance (ANCOVA) with adjustment of baseline measurement 
as well as adjustment of the length of time between two blood 
sample collection (30±15 minutes). The same analysis was 
carried out for secondary outcomes. Site monitoring, source data 
verification and trial master file review was carried out by the 
Sponsor and data management was performed by LSHTM using a 
bespoke electronic system.
Results
Recruitment to the ETAPlaT sub-study started on November 2013 
and finished on January 2015, with final follow-up completed in 
March 2015. During this time 187 patients were randomized to 
receive TXA (n=93) or placebo (n=94). Of these 17 patients in 
TXA group and 31 in placebo group (Figure 1) received a second 
dose of TXA or placebo. We were unable to collect baseline or 
follow up blood samples as emergency situation was ongoing in 
six patients and these patients were excluded from the analyses.
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Maternal Age - years                       mean (SD) 27.8 (5.6) 27.0 (5.6) 
Body Mass Index- kg/m²                 mean (SD) 28.5 (3.1) 29.9 (4.8)
Gestational age at birth–weeks       mean (SD) 38.3 (2.8) 38.2 (3.4)
FetalBirthweight – g.                      mean (SD)   3185 (695.2) 3222 (843.8)
Hemoglobin - g/dL+                        mean (SD)  10.8 (1.8) 11.4 (1.6)
Fibrinogen - g/L                               mean (SD) 3.6 (1.1) 3.5 (1.2)
Platelet count -10³/mm³                   mean (SD) 229.3 (80.4) 233.7 (80.1)
Blood lost mL                                  mean (SD) 863.2 (270.7) 893.1 (219.9)
Vaginal births Labor stages   - First stage(hrs) 
Mean (SD) [N]                   Second stage (min) 
                                              Third stage (min)
6.7 (4.3) [71]* 
40.5 (26.0) [67]* 
10.9 (9.1) [66]*
7.8 (4.1) [68]* 
48.5 (31.6) [66]* 
13.5 (12.4) [65]*
Parity : N (%)                                      Nullipara 
                                                          Multipara
57 (61.3 %) 
36 (38.7 %)
60 (63.8 %) 
34 (36.2 %)
Type of delivery: N (%)                         Vaginal 





Primary cause PPH: N (%)      Placenta previa 
                                     Surgical trauma / tears 
                                     Uterine atony 
                                     Other         











Preeclampsia: N (%)                                   Yes 
                                                               No      
11 (11.8 %) 
82 (88.2 %)
7 (7.4 %) 
87 (92.6 %)
Chorioamnionitis: N (%)                              Yes 
                                                                     No
5 (5.4 %) 
88 (94.6 %)
6 (6.4 %) 
88 (93.6 %)
Placental abruption: N (%)                          Yes 
                                                                     No 
9 (9.7 %) 
84 (90.3 %)
5 (5.3 %) 
89 (94.7 %)
Anaemia: N(%)                                            Yes 
                                                                     No
34 (36.6 %) 
59 (63.4 %)
23 (24.5 %) 
71 (75.5 %)
Previous PPH: N (%)                                   Yes 
                                                                     No
3 (3.2 %) 
90 (96.8 %)
6 (6.4 %) 
88 (93.6 %)
Hematologic disease N (%)                        Yes 
                                                                     No




Treatment with antithrombotics N (%)         Yes 
                                                                     No
0 (0%) 
93 (100 %)
2 (2.1 %) 
92 (97.9 %)
* Patients vaginal delivery;+ p-value Wilcoxon-Mann-Whitney-Test: 0.01
The baseline data for TXA and placebo groups were similar 
(Table 1). One patient (TXA group) was known to have von 
Willebrand disease. The main cause of PPH in both groups was 
uterine atony. In the TXA group, the median (mean) time difference 
between both samples is 31.00 (32.98) minutes.
In the placebo group, the median (mean) time difference 
between both samples is 30.00 (31.74) minutes. In TXA group, 
the minimum (maximum) time difference between both samples 
is 20.00 (45.00) minutes. In placebo group, the minimum 
(maximum) time difference between both samples is 15.00 
(63.00) minutes. There is no evidence that time differences differ 
between both treatment groups (Wilcoxon-Mann-Whitney-Test, 
p = 0.1336).
Primary outcome - results
The change in ETP (expressed in nM*min) between baseline and 
follow-up was 43.2 (95%CI, -16.6 to 103.1) in the TXA treated 
group and 4.6 (95%CI, -51.4 to 60.6) in the placebo group. The 
difference in differences (DiD) of 36.63 (TXA minus Placebo) 





to 120.0). The detailed values are given in Table 2.
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Mean Difference (95% CI)
DID: TXA / Placebo groups 
Mean DID ( 95%CI) p Value
ETP(nM*min)
TXA (N=87) 1537 (375.9) 1494 (369.1) 43.2 [-16.6; 103.1] 36.63 [-42.9; 120.0] praw = 0.350* 
29.81 [-47.8; 107.4] padj = 0.453**Placebo (N=94) 1491 (378.7) 1487 (390.5) 4.6 [-51.4; 60.6]
ADPtest(AU*min)
TXA (N=89) 1043.0 (343.6) 964.7 (312.4) 78.0 [15.4; 140.6] 13.2 ( -65.8; 92.2) praw= 0.7* 
-0.9 ( -72.7; 70.9) padj = 1.0**Placebo (N=91) 961.6 (339.6) 896.8 (356.8) 64.8 (15.8; 113.7)
TRAPtest(AU*min)
TXA (N=89) 1199 (362.3) 1093 (300.3) 106.2 (38.5; 174.0) 20.9 ( -65.3; 107.1) praw= 0.6* 
1.5 ( -72.8; 75.7) padj = 1.0**Placebo (N=91) 1156 (347.9) 1070 (336.8) 85.3 (31.2; 139.4)
Factor V (%)
TXA (N=88) 103.4 (27.7) 103.4 (25.7) 0.1 (-4.6; 4.8) -4.2 ( -10.0; 1.7) praw= 0.2* 
-4.9 ( -10.4; 0.7) padj = 0.1**Placebo (N=94) 100.2 (28.5) 95.9 (29.2) 4.3 (0.7; 7.8)
Factor VIII (%)
TXA (N=88) 221.9 (102.4) 216.1 (87.4) 5.9 (-9.5; 21.2) 5.9 ( -13.9; 25.6) praw= 0.6* 
-0.9 ( -18.7; 17.6) padj = 1.0**Placebo (N=94) 195.2 (87.0) 195.2 (87.4) 0.0 (-12.7; 12.7)
Factor vW (%)
TXA (N=88) 219.4 (89.8) 222.2 (89.1) -2.8 (-15.2; 9.7) -0.1 ( -16.9; 16.7) praw= 1.0* 
1.3 ( -15.0; 17.5) padj = 0.9**Placebo (N=94) 212.6 (92.6) 215.3 (92.0) -2.7 (-14.1; 8.8)
Fibrinogen (g/L)
TXA (N=87) 3.64 (1.09) 3.59 (1.07) 0.05 (-0.1; 0.2) -0.08 (-0.29; 0.12) Praw= 0.4* 
-0.09 (-0.28; 0.1) padj = 0.4**Placebo (N=93) 3.49 (1.2) 3.36 (1.1) 0.13 (-0.01; 0.27)
D-Dimer (mg/L)
TXA (N=88) 7.4 (9.3) 7.8 (10.2) -0.4 (-1.1; 0.3) 0.9 ( -1.3; 3.0) praw= 0.4* 
1.5 ( -0.2; 3.1) padj = 0.1**Placebo (N=94) 9.6 (24.6) 10.8 (17.7) -1.3 (-3.4; 0.8)
Population: Patients were difference could be calculated (N); DID: Difference in Differences 
Analysis: * raw (simple 95% CI of DID); ** adjusted for baseline and time between samples
Secondary outcomes - results
Table 2 also summarizes the exploratory results for the secondary 
outcomes. The change in platelet activity (expressed in AU*min) 
in the ADPtest was larger with TXA (mean change 78.0, 95%CI, 
15.4 to 140.6) compared to placebo group (mean change 64.8, 
95%CI, 15.8 to 113.7), but with no significant difference in 
difference (DiD 13.2, 95%CI, -65.8 to 92.2). The mean difference 
of the TRAPtest for the TXA group was 106.2, (95%CI, 38.5 
to 174.0) compared to the placebo group 85.3, (95%CI, 31.2 
to 139.4). The difference in difference was not significant 
(DiD -20.9, 95%CI, - 65.3 to 107.1). There was no significant 
DiD between treatment groups for coagulation factors activity 
(expressed in % of the norm). The results are as follows: 
factors V DiD -4.2, 95%CI, -10.0 to 1.7, factor VIII DiD 
5.9, 95%CI, -13.9 to 25.6, and von Willebrand factor DiD -0.1, 
95%CI, -16.9 to; 16.7. No significant difference in difference 
was observed for Fibrinogen, expressed in g/L, (DiD -0.08 
with 95%CI, -0.29 to 0.12) or D-Dimer, expressed in mg/L, 
(DiD 0.9 with 95%CI, -1.3 to 3.0). Detailed changes in the 
single treatment groups are presented in Table 2.
Discussion
We found no evidence that tranexamic acid (TXA) has large 
effects on thrombin generation or platelet function. However, we 
cannot exclude the possibility of more modest effects. Thrombin 
plays a crucial role in coagulation15 and increased thrombin 
generation is associated with an increased risk of thrombosis19. 
Plasmin has been shown to increase thrombin formation in the 
blood of healthy volunteers in vitro8. An increase in thrombin 
generation by plasmin was also reported during treatment with 
tissue plasminogen activators20. ETP was decreased about 30% 
after administration of very effective anticoagulant agents such 
as low-molecular-weight heparin, in postpartum period soon after 
caesarean delivery21 and also during pregnancy at an in-vitro 
study22. In our study there was a small decrease (3%) in ETP with 
TXA administration (DiD 36.63, 95% CI, -120; 42.8) that was 
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not statistically different to that seen in the placebo group. This 
study provides no evidence TXA has a pro-thrombotic effect.
Plasmin has multifactorial pro-coagulant effects on platelet 
activation10,23. Activation of platelets may contribute to thrombus 
formation24. The evaluation of platelet activity using MEA with 
ADPtest and TRAPtest provides information about the thrombotic 
risk. The reported range for healthy volunteers of ADPtest was 
483 to 1173 AU*min. The reported range for the TRAPtest was 
897 to 1469 AU*min.25. The observations of our study are 
comparable within both treatment groups and in a good fit with 
the results of Rubak25. They show a modest decrease in platelet 
activity in both tests in TXA group compared to placebo, but the 
difference was not statistically significant. Once again, these results 
provide no evidence that TXA has pro-thrombotic effects.
In the last trimester of pregnancy, plasma levels of plasminogen 
and fibrinogen increase by about 50% whilst levels of plasmino-
gen activator inhibitors 1 and 2 increase 3-fold and 25-fold, 
respectively7 . Immediately following delivery there is early 
fibrinolytic activation and this can be inhibited by TXA26. The 
inhibition of fibrinolysis with TXA has the potential to increase 
thrombotic risk27. By reducing fibrinolysis, TXA can help to 
maintain  fibrinogen levels. In our study, the drop in fibrinogen 
(DiD -0.08, 95%CI -0.29; to 0.12) was smaller in the TXA group 
but again the difference was not statistically significant.
Study limitations
The study was designed to prove a difference (more relevant 
changes with the use of TXA compared to placebo) and was 
not planned to establish therapeutic equivalence. There are no 
predefined therapeutic equivalence bounds which would allow 
an objective comparison between derived DiD confidence 
intervals. The study uses a large series of secondary endpoints 
and multiple testing performed in an explorative setting. In the 
ETAPlaT study, although we did not measured plasmin directly but 
evaluated thrombin generation and platelet function as an indirect 
effect of TXA on plasmin inhibition. Some post-randomization 
exclusions were performed, because of the emergency situation of 
PPH it was difficult to collect the baseline or follow up or both 
blood samples.
Conclusion
Although the inhibition of fibrinolysis with TXA has the potential 
to increase thrombotic risk, we found no increase in thrombin 
generation and no increase in platelet activity with TXA.
Ethics approval and consent to participate
Ethical approval for WOMAN ETAPlaT protocol was obtained 
from the London School of Hygiene and Tropical Medicine 
Ethics Committee, United Kingdom, and by the National Ethics 
Committee in Tirana, Albania. ETAPlaT study was undertaken 
according to local regulatory requirements, and adhered the 
ICH-GCP guidelines. The consent procedure was approved 
by each Ethics Committee and is detailed in the previously 
published WOMAN trial and ETAPLaT protocols4,11. Briefly, 
consent was obtained from a woman if her physical and mental 
capacity allowed (as judged by the treating clinician). If a woman 
was unable to give consent, proxy consent was obtained from a 
relative or representative (who was not involved in the trial and 
was approved by the hospital). If a proxy was unavailable, then 
as permitted by local ethics approval, consent was deferred. 
When consent was deferred or given by a proxy, the woman was 
informed about the trial as soon as possible, and consent was 
obtained for ongoing data collection, if needed.
Data availability
The anonymised data used for this publication is available from 
the freeBIRD data portal at https://freebird.lshtm.ac.uk/index.
php/data-sharing/downloads/etaplat/ following free registration: 
http://www.doi.org/10.17037/DATA.0000097028. Data are avail-
able under an Open Data Commons Attribution License (ODC-By) 
licence.
Reporting guidelines
This study is compliant with CONSORT guideline 
recommendations29.
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